The current analysis showed that although mild hepatic impairment, classified by elevated transaminase or bilirubin levels, showed a weak trend towards increased nintedanib exposure, it did not meet the significance criteria based on the forward inclusion–backward elimination procedure to be included in the final model.
← all excerpts
Population pharmacokinetics of nintedanib, an inhibitor of tyrosine kinases, in patients with non-small cell lung cancer or idiopathic pulmonary fibrosis.
1
—
—